ClinTrial Refer

Trial Acronym
PRIME PsO

Registration Number
NCT04911751

Scientific Title
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of KBL697 in Patients With Moderate Plaque Type Psoriasis

The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate Plaque Type Psoriasis. KBL697 has been developed as a potential new treatment for Psoriatic Plaque.

-  Male or female, aged 18 to 75 years (inclusive)

    -  Have a diagnosis of plaque type psoriasis for => 6 months

    -  Must have chronic plaque type psoriasis of moderate severity

    -  All subjects must agree and commit to the use of a reliable contraceptive regimen.

-  Current diagnosis of forms of psoriasis other than chronic plaque type only

    -  Drug-induced psoriasis

    -  Other inflammatory skin disease that may confound the evaluation of plaque psoriasis

    -  Failed 2 or more systemic treatments for plaque psoriasis

    -  Medicinal shampoos that contain tar and/or salicylic acid within 2 weeks prior to Baseline Visit

Trial Location Name

Address

Status

Indago Research and Health Center Inc.

3700 West 12th Avenue suite 300, Hialeah, Florida 33012, USA

Closed

Primary Contact : Karel Reyes, kreyes@indagoresearch.org , 1-305-825-6588

Secondary Contact : Francina Sanchez, fsanchez@indagoresearch.org , 13058256588

Louisiana Dermatology Associates - Dermatology

Louisiana Dermatology Associates, 10154 Jefferson Highway, Baton Rouge, Louisiana 70809, USA

Closed

Primary Contact : Hilary Kingsley, hkingsley@delricht.com , 1-504-336-2667

Secondary Contact : Kandice Lemoine, klemoine@delricht.com , 15043362667

Revival Research

8200 Northwest 27th Street suite 116, Doral, Florida 33122, USA

Closed

Primary Contact : Patricia Benet, Pbenet@revivalresearch.com , 1-305-982-8892

Secondary Contact : Iridalia Gonzalez, igonzalez@revivalresearch.com , 13059828892

Sinclair Dermatology

level 3/2 Wellington Parade, East Melbourne VIC 3002, Australia

Closed

Primary Contact : Coordinator: Carolyn De Silva, Carolyn.desilva@sinclairdermatology.com.au , 03 9013 0099

Secondary Contact : PI: Dr Samantha Eisman, sameisman@gmail.com

Southern California Dermatology Inc

1125 East 17th Street suite w248, Santa Ana, California 92701, USA

Closed

Primary Contact : Natalie Soto, natalie@ocallergy.com , 1-714-474-2173

Secondary Contact : Jocelyn Parra, jparrasocalderm@gmail.com , 17144742173

Total Skin and Beauty Dermatology Center PC

Total Skin & Beauty Dermatology Center, 16th Avenue South, Birmingham, AL, USA

Closed

Primary Contact : Angela Powell, angela@totalskinandbeauty.com , 1-205-380-6148

Secondary Contact : Brittany Powell, Brittanyp@totalskinandbeauty.com , 12053806148

Veracity Clinical Trials Ltd (Dermatology)

suite 18 level 1/250 Ipswich Road, Woolloongabba Queensland 4102, Australia

Closed

Primary Contact : Coordinator: Kurt Davidson, kdavidson@veracityclinicalresearch.com.au , +61 730 391 346

Secondary Contact : PI: Prof. Lynda Spelman, spelchat@veracity.net.au

Westmead Hospital (Dermatology)

Darcy Road & Hawkesbury Road, Westmead NSW, Australia

Closed

Primary Contact : Clinical Trials Coordinator, WSLHD-Dermatology-ClinicalTrials@health.nsw.gov.au , 02 8890 5686

Secondary Contact : Dermatology Admin, WSLHD-WestmeadDermatology@health.nsw.gov.au , 88907149

KoBioLabs Australia Pty Ltd

Website URL

Link Name

Link URL

ANZCTR

http://www.anzctr.org.au/TrialSearch.aspx?searchTxt=NCT04911751

Clinicaltrials.gov

https://clinicaltrials.gov/ct2/show/NCT04911751

Secondary IDs
KBL-CURE-2020-02

Study Type
Interventional

Intervention Code
Treatment - Drugs

Phase
Phase 2

Minimum Age
18

Maximum Age
75

Date Registered
28/07/2022

Date Closed
N/A

Status
Closed

Enrolment Type
By Self-Referral,Primary Care or GP Referral

Mutation Status and Biomarker
Any or not stated

Is it a Cohort Trial?
No

Is this a Tele-Trial?
No

Can healthy volunteer participate?
No

Discipline

Health Condition

Back to List/Filter

to List/Filter